ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This research study focuses on a rare type of acute myeloid leukemia (with the subtype
CBFA2T3::GLIS2 that overexpresses folate receptor alpha (FRĪ±) (a protein on the surface of
leukemia cells)) that has relapsed or is refractory. Relapse means the cancer has come back
after treatment. Refractory means the cancer does not respond to treatment.
ELU001 is a new chemical entity described as a C'Dot drug conjugate (CDC), consisting of
payloads (exatecans) and targeting moieties (folic acid analogs) covalently bound by linkers
to the C'Dot particle carrier. ELU001 will be the first drug-conjugate of its kind to be
introduced into the clinic, a first in class, and a novel molecular entity.
Phase:
Phase 1
Details
Lead Sponsor:
Elucida Oncology
Collaborator:
Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL)